Chinese pharmaceutical companies are thriving in new drug development, with approximately 40% of drugs licensed by pharmaceutical companies in 2026 being discovered in China[5]. Chinese biotech firms are particularly dominant in the field of oncology – they are responsible for about 70% of the global development of drug-conjugated antibodies (ADCs) used in targeted cancer therapies and about 60% of bispecific antibodies[3]. In 2025, Chinese pharmaceutical manufacturers will reach a record $135.7 billion through 157 international licensing agreements, a significant increase from $51.9 billion in 2024[6]. China's pharmaceutical market is expected to grow at a CAGR of 7.8% during the period 2026 to 2033[1]. More clinical trials have been launched in China than in any other country, surpassing the United States for the first time[5]. Global pharmaceutical companies, including Pfizer and AstraZeneca, are making significant investments in China to gain access to cost-effective clinical trial pipelines and innovation capacity[1][4].